CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31
CareDx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$67.08+3.08 (+4.81%)
Close on Oct 19, 2026
- Market cap
- $3.58B
- P/E (TTM)
- 32.4
- Dividend yield
- –
CareDx, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing services revenue | $99.93M | $91.40M | $78.37M | $72.17M | $62.03M | $61.92M | $63.82M | $60.81M | $70.92M | $53.84M | $46.70M | $47.78M | 75.7% | +61.1% |
| Patient and digital solutions revenue | $19.23M | $15.96M | $16.76M | $15.41M | $12.81M | $11.95M | $11.39M | $11.86M | $10.75M | $9.62M | $9.62M | $9.87M | 14.6% | +50.1% |
| Product revenue | $12.79M | $10.35M | $13.26M | $12.48M | $11.83M | $10.81M | $11.37M | $10.21M | $10.61M | $8.59M | $9.24M | $9.54M | 9.7% | +8.1% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $126.63M | $113.65M | $103.38M | $95.06M | $81.64M | $79.87M | $82.17M | $79.08M | $87.97M | $68.51M | $62.08M | $63.19M | 96.0% | +55.1% |
| Rest of World | $5.32M | $4.05M | – | – | $5.04M | $4.82M | – | – | – | – | – | – | 4.0% | +5.6% |
| Europe | – | – | – | – | – | – | $2.98M | $2.52M | $2.86M | $2.31M | $2.50M | $2.47M | – | – |
| Rest of World | – | – | – | $5.00M | $5.04M | $4.82M | – | $3.80M | $4.31M | $3.54M | – | $1.53M | – | – |
From the segment and revenue-disaggregation notes of CareDx's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.